BridgeBio is substantially improved its development of a new treatment for cardiac amyloidosis, leveraging the compound. Preliminary patient data suggests promising outcomes for those affected by this serious disease. https://biotech546180.blogdeazar.com/42499879/bridgebio-improves-amyloidosis-treatment-through-the-drug